Antidepressant mechanism of Baihe Dihuang Decoction based on metabolomics and network pharmacology.
10.19540/j.cnki.cjcmm.20240712.710
- Author:
Chao HU
1
;
Hui YANG
1
;
Hong-Qing ZHAO
2
;
Si-Qi HUANG
2
;
Hong-Yu LIU
1
;
Shui-Han ZHANG
3
;
Lin TANG
1
Author Information
1. the First Hospital of Hunan University of Chinese Medicine Changsha 410007, China.
2. Hunan University of Chinese Medicine Changsha 410208, China.
3. Hunan Academy of Chinese Medicine Changsha 410208, China.
- Publication Type:Journal Article
- Keywords:
Baihe Dihuang Decoction;
depression;
mechanism;
metabolomics;
network pharmacology
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Male;
Rats, Sprague-Dawley;
Rats;
Metabolomics;
Depression/genetics*;
Antidepressive Agents/chemistry*;
Network Pharmacology;
Hippocampus/drug effects*;
Humans;
Molecular Docking Simulation;
Behavior, Animal/drug effects*;
Disease Models, Animal
- From:
China Journal of Chinese Materia Medica
2025;50(1):10-20
- CountryChina
- Language:Chinese
-
Abstract:
The Baihe Dihuang Decoction(BDD) is a representative traditional Chinese medicine formula that has been used to treat depression. This study employed metabolomics and network pharmacology to investigate the mechanism of BDD in the treatment of depression. Fifty male Sprague-Dawley(SD) rats were randomly assigned to the normal control group, model group, fluoxetine group, and high-and low-dose BDD groups. A rat model of depression was established through chronic unpredictable mild stress(CUMS), and the behavioral changes were detected by forced swimming test and open field test. Metabolomics technology was used to analyze the metabolic profiles of serum and hippocampal tissue to screen differential metabolites and related metabolic pathways. Additionally, network pharmacology and molecular docking techniques were used to investigate the key targets and core active ingredients of BDD in improving metabolic abnormalities of depression. A "component-target-metabolite-pathway" regulatory network was constructed. BDD could significantly improve depressive-like behavior in CUMS rats and regulate 12 differential metabolites in serum and 27 differential metabolites in the hippocampus, involving tryptophan metabolism, phenylalanine, tyrosine, and tryptophan biosynthesis, alanine, aspartate, and glutamate metabolism, tyrosine metabolism, and purine metabolism. Verbascoside, isorbascoside, and regaloside B were the key active ingredients for improving metabolic abnormalities in depression. Epidermal growth factor receptor(EGFR), protooncogene tyrosine-protein kinase(SRC), glycogen synthase kinase 3β(GSK3β), and androgen receptor(AR) were the key core targets for improving metabolic abnormalities of depression. This study offered a preliminary insight into the mechanism of BDD in alleviating metabolic abnormalities of depression through network regulation, providing valuable guidance for its clinical use and subsequent research.
